<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00256191</url>
  </required_header>
  <id_info>
    <org_study_id>TPI 287-02</org_study_id>
    <nct_id>NCT00256191</nct_id>
  </id_info>
  <brief_title>Study of TPI 287 Administered Every 21 Days in Patients With Advanced Malignancies</brief_title>
  <official_title>A Phase 1, Open-Label, Q21 Day Dose Escalation, Multi-Center Study of TPI 287 in Patients With Advanced Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cortice Biosciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cortice Biosciences, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Tapestry Pharmaceuticals, Inc. has developed a novel taxane analog, TPI 287. TPI 287 is&#xD;
      synthetically manufactured from naturally occurring taxanes extracted from yew starting&#xD;
      material. The synthesis involves modification to the taxane side chain to overcome multidrug&#xD;
      resistance and to achieve mutant tubulin binding. This study will be a multi-center, dose&#xD;
      escalation, sequential group, Phase 1 study evaluating the intravenous administration of TPI&#xD;
      287 on an every 21 day cycle.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study is to determine the maximum tolerated dose of TPI 287&#xD;
      administered every 21 days for Phase II clinical trials.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2005</start_date>
  <completion_date type="Actual">February 2007</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the maximum tolerated dose of TPI 287 administered every 21 days</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine the safety of TPI 287</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the antitumor activity of TPI 287</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the pharmacokinetic profile of TPI 287</measure>
  </secondary_outcome>
  <enrollment>45</enrollment>
  <condition>Neoplasms</condition>
  <condition>Hodgkin's Disease</condition>
  <condition>Non-Hodgkin's Lymphoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TPI 287 Injection</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients must be/have:&#xD;
&#xD;
          -  Histological evidence of malignancy&#xD;
&#xD;
          -  Advanced solid tumors that have recurred or progressed following standard therapy&#xD;
&#xD;
          -  Failed one prior therapy or have no standard therapy available&#xD;
&#xD;
          -  Ambulatory with ECOG of 0-1 and estimated life expectancy of &gt; 3 months&#xD;
&#xD;
          -  If female, negative pregnancy test&#xD;
&#xD;
          -  If of childbearing years, agree to use birth control&#xD;
&#xD;
          -  If patient with prior radiation therapy for brain metastases, on steroids, must have&#xD;
             been stable for 1 month&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patients will be excluded if they are or have had:&#xD;
&#xD;
          -  Prior radiation within 4 weeks&#xD;
&#xD;
          -  Active medical condition or organ disease which may compromise safety or interfere&#xD;
             with the study&#xD;
&#xD;
          -  Clinically significant cardiac co-morbidities or pulmonary impairment&#xD;
&#xD;
          -  Concomitant therapy needs&#xD;
&#xD;
          -  Treated with any investigational drugs within 30 days&#xD;
&#xD;
          -  Tumors involve major artery or vein&#xD;
&#xD;
          -  Prior or concurrent central nervous system (CNS) disease&#xD;
&#xD;
          -  Less than 4 weeks since major surgery&#xD;
&#xD;
          -  Known to be positive for HIV, hepatitis B or C&#xD;
&#xD;
          -  Concurrent use of aspirin&#xD;
&#xD;
          -  Use of thrombolytic agents&#xD;
&#xD;
          -  Uncontrolled hypertension&#xD;
&#xD;
          -  Grade II-IV peripheral vascular disease&#xD;
&#xD;
          -  Pregnant or lactating&#xD;
&#xD;
          -  Prior allergic history to compounds of similar chemical composition&#xD;
&#xD;
          -  Inpatients&#xD;
&#xD;
          -  Grade II-IV peripheral neuropathy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sandra Silberman, MD</last_name>
    <role>Study Director</role>
    <affiliation>Tapestry Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.tapestrypharma.com</url>
    <description>Click here for more information about this study. A Phase 1, Open-Label, Q21 Day Dose Escalation, Multi-Center Study of TPI 287 in Patients with Advanced Malignancies</description>
  </link>
  <verification_date>November 2005</verification_date>
  <study_first_submitted>November 16, 2005</study_first_submitted>
  <study_first_submitted_qc>November 16, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 21, 2005</study_first_posted>
  <last_update_submitted>October 11, 2007</last_update_submitted>
  <last_update_submitted_qc>October 11, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 15, 2007</last_update_posted>
  <keyword>taxanes</keyword>
  <keyword>multidrug resistance</keyword>
  <keyword>mutant tubulin binding</keyword>
  <keyword>Hodgkin's or Non-Hodgkin's Lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

